Posted by : admin in (About Lawsuit Funding, Plaintiff Funding)

We Now Fund Accutane, Avandia, Bextra, Celebrex, Fosamax and more!

Tagged Under : , , , , , , , , ,

You Can Get Cash Now From Your Pharmaceutical Settlement!

TriMark Capital Funding, Inc. has exciting news pertaining to a variety of pharmaceutical MDL’s (multi-district litigation) or class action lawsuits.

Wyeth v. Levine was decided by the US Supreme Court on March 4, 2009 . The issue was that of “pre-emption”, and it is now considered a moot point. Stated plainly, the Supreme Court has decided that even though drug manufacturers provide a warning label, injured parties can still pursue “failure to warn” litigation.

TCF is now moving aggressively funding cash advances on the following pharmaceutical class action lawsuits:

  • Accutane
  • Avandia
  • Bextra
  • Celebrex
  • Duragesic Patch
  • Gadolinium
  • Fosamax
  • Kugel Mesh
  • Ortho Evra
  • Prempro

This is a MAJOR breakthrough in litigation financing and TCF is one of the only litigation funding companies in the entire United States currently offering lawsuit cash advances and pre-settlement funding on Accutane, Avandia, Bextra, Celebrex, Duragesic Patch, Gadolinium, Fosamax, Kugel Mesh and Prempro class action lawsuits.

Visit LawsuitLoanHQ.com for more information or to apply for a lawsuit cash advance now!

No Comments
Read More

Posted by : admin in (Plaintiff Funding)

What are Vioxx Lawsuit Loans?

VIOXX LAWSUIT – VIOXX SETTLEMENT FUNDING

Well, technically speaking, Vioxx lawsuit loans are not actually loans at all; they’re non-recourse cash advances (also called Vioxx settlement funding) provided by lawsuit funding companies like LawsuitLoanHQ.com and will be repaid out of the pending Vioxx settlement that plaintiffs hope to begin receiving later this year.

In September 2007 Merck agreed to a $4.85 billion dollar settlement in response to lawsuits filed on behalf of people injured or killed as a result of taking the prescription painkiller Vioxx.

According to USA Today, as of today, more than 44,000 people have submitted either all or a portion of the paperwork required for them to be enrolled in the Vioxx settlement deal. People who enrolled by February 29, 2008 whose claims are verified will be eligible for an interim, partial payment due to begin being disbursed in August of this year.

Merck withdrew Vioxx from the market voluntarily in 2004 after one of its own medical studies revealed that Vioxx doubled the risk of stroke and heart attack. According to Merck, Vioxx accounted for $2.5 billion of it’s 2003 sales volume and approximately 15% of the company’s profit for that year.

(1) Comment
Read More